R7 (drug)

R7
Clinical data
Other names4-Oxo-2-phenyl-4H-chromene-7,8-diyl bis(dimethylcarbamate)
Routes of
administration		By mouth
Legal status
Legal status
Pharmacokinetic data
Bioavailability~35% (in mice)
MetabolitesTropoflavin
Elimination half-life~3.25 hours (in mice
Identifiers
  • [8-(Dimethylcarbamoyloxy)-4-oxo-2-phenylchromen-7-yl] N,N-dimethylcarbamate
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC21H20N2O6
Molar mass396.399 g·mol−1
3D model (JSmol)
  • CN(C)C(=O)OC1=C(C2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3)OC(=O)N(C)C
  • InChI=1S/C21H20N2O6/c1-22(2)20(25)28-16-11-10-14-15(24)12-17(13-8-6-5-7-9-13)27-18(14)19(16)29-21(26)23(3)4/h5-12H,1-4H3
  • Key:KHUMQRAGNPGBIE-UHFFFAOYSA-N

R7 is a small-molecule flavonoid and orally active, potent, and selective agonist of the tropomyosin receptor kinase B (TrkB) – the main signaling receptor for the neurotrophin brain-derived neurotrophic factor (BDNF) – which is under development for the treatment of Alzheimer's disease. It is a structural modification and prodrug of tropoflavin (7,8-DHF) with improved potency and pharmacokinetics, namely oral bioavailability and duration.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.